{"id":"417b168f7837","type":"article","url":"https://hartvaat.nl/2018/02/01/bnp-prognostische-waarde-bij-hartfalen-met-lvef-35/","title":"BNP-prognostische waarde bij hartfalen met LVEF >35%","title_en":"The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","hfpef","hfref","nt-probnp","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.12206","source_url":"https://doi.org/10.1002/ehf2.12206","authors":["Shuichi Kitada","Shohei Kikuchi","Takeshi Tsujino","Tohru Masuyama","Nobuyuki Ohte"],"significance":5,"published":"2018-02-01","source_date":"2018-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This study evaluated the prognostic value of BNP in heart failure patients with relatively preserved ejection fraction (>35%), refining natriuretic peptide-based risk stratification for the HFmrEF/HFpEF population.","created":"2026-07-03T10:27:07Z","updated":"2026-07-03T18:38:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar de prognostische waarde van BNP bij hartfalenpatiënten met relatief behouden ejectiefractie (>35%). Relevant voor risicostratificatie bij de grijze zone van LVEF.","abstract_original":"AIMS: Cardiac function varies in the population of patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF; HFpEF). This study investigated the heterogeneity of clinical features associated with HF and the prognostic value of BNP levels in patients with HFpEF. METHODS AND RESULTS: The study enrolled 288 patients with stable HF and serum creatinine <1.5 mg/dL who were part of the original J-MELODIC study cohort. They were categorized as having HF with reduced LVEF (HFrEF; EF ≤ 40%, n = 83) or as having HFpEF (EF > 40%, n = 205). Patients with HFpEF were further categorized as having relatively low LVEF (HFrlEF; EF 40-60%, n = 107) or as having relatively high LVEF (HFrhEF; EF ≥ 60%, n = 98). We defined cardiovascular death and hospitalization for HF as adverse events and evaluated the prognostic value of the BNP levels in each group. There was no significant difference in event-free survival between HFpEF and HFrEF patients or between HFrhEF and HFrlEF patients. A multivariate Cox proportional hazards model revealed that the BNP level was an independent predictor of adverse events in HFrEF patients (hazard ratio: 4.088, 95% confidence interval: 1.178-14.179, P = 0.027) and in HFrlEF patients (hazard ratio: 14.888, 95% confidence interval: 4.969-44.608, P < 0.001) but not in HFrhEF patients (P = 0.767). CONCLUSIONS: The BNP level has prognostic value in HFrlEF but not in HFrhEF. This indicates that HFrhEF and HFrlEF are distinct entities that may require different approaches for the management of HF."}